Small-molecule protein degrader drug discovery platform targeting neurodegenerative diseases including Huntington's and Alzheimer's.
Origami Therapeutics develops novel small-molecule protein degraders that selectively eliminate toxic, disease-causing proteins while sparing normal forms, enabling broad body distribution and ease of manufacture. Proprietary human disease models guide selection of small molecules most likely to achieve clinical success. Primary indications include Huntington's disease, Alzheimer's, Parkinson's, ALS, and Frontotemporal Dementia. Pre-clinical work has demonstrated reduction of toxic mutated protein and suppression of protein-induced toxicities in human models. Origami Therapeutics is a product of Origami Therapeutics, Inc..